Is intramuscular testosterone actually superior to other TRT routes?

What's this video probably claiming?

A TikTok account called @anabolic_insights, operating squarely in the bodybuilder-meets-TRT content niche, is almost certainly making the case that intramuscular (IM) testosterone injections, probably cypionate or enanthate, are the superior delivery method compared to transdermal gels, patches, or subcutaneous injections. The framing of "intramuscular superiority" is a common talking point in gym-adjacent TRT communities, where injectable testosterone gets treated as the gold standard not just for clinical hypogonadism but for performance optimization. The video likely argues that IM delivers more consistent serum levels, better absorption, or stronger anabolic effect. The bodybuilder hashtag signals this is probably being framed through a lens of physique optimization, not strictly medical management of hypogonadism, which matters a great deal when evaluating what claims are being made and to whom.

What does the science actually show?

The clinical picture is genuinely more nuanced than "IM wins." A 2021 comparison by Grech et al. published in the Journal of Clinical Endocrinology and Metabolism found that subcutaneous testosterone injections produced bioavailable testosterone levels comparable to IM injections with a more favorable pharmacokinetic profile and less injection-site discomfort. Meanwhile, transdermal gels, when applied consistently and correctly, have been shown to maintain stable steady-state testosterone levels. The 2010 Testim phase-3 trial data showed mean serum testosterone levels held within the normal range (300-1000 ng/dL) across 90 days in roughly 72% of patients. The real differentiator between delivery methods is not raw anabolic potency but individual absorption variability, injection frequency tolerance, cost, and patient preference. IM testosterone cypionate does produce peak-trough swings, with peaks sometimes exceeding 1500 ng/dL in the days post-injection before troughing, which many clinicians now consider a drawback rather than a feature.

Where does the social media noise diverge from clinical reality?

The bodybuilder TRT space conflates clinical testosterone replacement with performance enhancement regularly, and this video appears to be operating in that grey zone. Clinically, the Endocrine Society's 2018 guidelines do not rank delivery methods by superiority. They recommend individualizing treatment based on patient preference, cost, and side effect profile. The claim that IM is superior largely depends on what you are optimizing for. If you want supraphysiologic peaks, yes, IM cypionate weekly or biweekly will deliver them. But that is not a therapeutic goal for hypogonadism management; it is a performance goal. Several studies, including Dobs et al. (1999, Clinical Pharmacology and Therapeutics), documented that wide testosterone fluctuations from biweekly IM injections were associated with greater mood variability and erythrocytosis risk compared to steadier delivery methods. The "superiority" framing is doing a lot of heavy lifting for what is really a preference argument dressed up as clinical fact.

What should you actually know?

If you are on TRT or considering it, delivery method selection should be a conversation with a licensed prescriber based on your lab values, lifestyle, and risk factors, not a TikTok recommendation. IM testosterone cypionate 100-200 mg per week is a commonly prescribed clinical range, but dosing, frequency, and method should never come from social media. Subcutaneous injections at smaller, more frequent doses (e.g., twice weekly) are gaining clinical traction precisely because they blunt peak-trough swings without sacrificing efficacy. A 2019 study by Olson et al. in Sexual Medicine found subQ testosterone produced statistically similar total testosterone levels to IM with better tolerability. The repeated suggestion in gym content that IM is inherently more anabolic or more effective for "optimization" lacks robust clinical support and is largely extrapolated from bodybuilding culture rather than evidence-based endocrinology. Route of administration matters far less than total weekly dose, injection frequency, and individual metabolic response.